share_log

公告精选 | 丘钛科技:11月摄像模组出货量同比增6.5%;世茂集团:前11个月累计销售额约400.1亿元

Selected announcements | Qiutai Technology: November camera module shipments increased 6.5% year on year; Shimao Group: Cumulative sales for the first 11 months were about 40.1 billion yuan

Futu News ·  12/08/2023 08:14

Big announcement

1. Qiutai Technology: The sales volume of mobile phone camera modules in November was 37.094 million units, an increase of 6.5% over the previous year

$Q TECH (01478.HK)$It was announced that in November 2023, the sales volume of mobile phone camera modules was 37.094 million units, up 8.1% month on month, up 6.5% year on year; total camera module sales volume was 37.948 million units, up 8.1% month on month and 5.7% year on year. The total number of fingerprint identification modules sold was 108.58 million, an increase of 16.1% over the previous year and a decrease of 5.9% over the previous year.

2. Shimao Group: The cumulative contract sales volume for the first 11 months was about 40.01 billion yuan, with a total area of about 2,745,700 square meters

$SHIMAO GROUP (00813.HK)$It was announced that for the 11 months ended November 30, 2023, the Group's cumulative contract sales volume was about RMB 40.1 billion, the total cumulative contract sales area was about 2,745,700 square meters, and the average sales price was RMB 14,573 per square meter; the contract sales volume of the Group in November 2023 was about RMB 2.43 billion, the contract sales area was about 197,900 square meters, and the average sales price was RMB 12,284 per square meter.

3. Hesheng Innovation Group: The total contract sales amount for the first 11 months was about 27.716 billion yuan, a year-on-year decrease of 1.41%

$HOPSON DEV HOLD (00754.HK)$It was announced that for the 11 months ended November 30, 2023, the total contract sales amount of the Group and its joint ventures and associated companies was approximately RMB 27.716 billion, a year-on-year decrease of 1.41%. Of these, property contract sales were approximately RMB 26.666 billion, and decoration contract sales were approximately RMB 1,050 million.

4. Connoah-B: Application for treatment of severe atopic dermatitis in adults with sposibaizumab was accepted by the National Drug Administration

$KEYMED BIO-B (02162.HK)$It was announced that the marketing application for spuchibaizumab injection was accepted by the State Drug Administration on December 7, 2023, and included in the priority review and approval process. According to reports, spuchibaizumab (R&D code CM310) is a highly effective, humanized antibody against the interleukin 4 receptor alpha subunit (IL-4Rα). It is the first domestically produced IL-4Rα antibody approved for clinical trials by the State Drug Administration.

5. Tencent Holdings spent HK$402 million to repurchase 1.31 million shares on December 7

$TENCENT (00700.HK)$An announcement was issued to repurchase 1.31 million shares at HK$402 million on December 7, 2023, at a repurchase price of HK$304.2,311 per share.

IPO News

$FAR International Holdings Group Company Limited (810466.HK)$Through the Hong Kong Stock Exchange hearing, a well-known cross-border e-commerce logistics service provider

$REPT BATTERO Energy Co., Ltd. (810457.HK)$Shares will be held from December 8 to December 13, and it is planned to issue 116 million shares

Operational data

$Q TECH (01478.HK)$The sales volume of mobile phone camera modules in November was 37.094 million units, an increase of 6.5% over the previous year

$SHIMAO GROUP (00813.HK)$Total cumulative contract sales for the first 11 months was approximately RMB 40.1 billion

$HOPSON DEV HOLD (00754.HK)$The total contract sales amount for the first 11 months was about 27.716 billion yuan, a year-on-year decrease of 1.41%

Company news

$XPENG-W (09868.HK)$Issuance of 81,250,000 Class A common shares to satisfy restricted share units

$CIFI HOLD GP (00884.HK)$The shares of the Tianjin Project Company were sold for 436 million yuan, and the proceeds were used to guarantee delivery and operation

$CHINA OVERSEAS (00688.HK)$It is planned to issue no more than 3 billion yuan of corporate bonds

$KEYMED BIO-B (02162.HK)$: Application for treatment of severe atopic dermatitis in adults with sposibaizumab was accepted by the State Drug Administration

$BEIGENE (06160.HK)$: Approximately 4.6022 million restricted shares will be listed and distributed from December 15

$HUTCHMED (00013.HK)$The subsidiary intends to sell its interest in the consumer products business

$ZAI LAB (09688.HK)$GRANT OF SHARE OPTIONS AND RESTRICTED SHARE UNITS

$WYNN MACAU (01128.HK)$Under the adopted share option scheme, 5,017 million share options were granted

Repurchase cancellation

$TENCENT (00700.HK)$On December 7, it spent HK$402 million to repurchase 1.31 million shares

$WUXI BIO (02269.HK)$On December 7, HK$390 million was spent to repurchase 13.161 million shares

$AIA (01299.HK)$On December 7, HK$135 million was spent to repurchase 2.156 million shares

$SINOPEC CORP (00386.HK)$On December 7, HK$56.883 million was spent to repurchase 146.84 million shares

$DONGFENG GROUP (00489.HK)$On December 7, it spent HK$27.142,900 to repurchase 7.112 million shares

$KUAISHOU-W (01024.HK)$On December 7, HK$26.885 million was spent to repurchase 500,000 shares

$COSCO SHIP HOLD (01919.HK)$On December 7, it spent HK$17.570,400 to repurchase 2,529,000 shares

$WANT WANT CHINA (00151.HK)$On December 7, it spent HK$11.227 million to repurchase 2.5 million shares

$POP MART (09992.HK)$On December 7, it spent HK$10.377 million to repurchase 500,000 shares

editor/tolk

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment